Intensive Care Medicine

, Volume 42, Issue 12, pp 2108–2110 | Cite as

Comparison of the qSOFA and CRB-65 for risk prediction in patients with community-acquired pneumonia

  • Martin Kolditz
  • André Scherag
  • Gernot Rohde
  • Santiago Ewig
  • Tobias Welte
  • Mathias Pletz
  • on behalf of the CAPNETZ Study Group

Dear Editors,

Community-acquired pneumonia (CAP) is a major source of sepsis, and sepsis-related acute organ dysfunction determines patient outcome. Therefore, early risk stratification using clinical scores such as the CRB(-65) and subsequent evaluation for organ dysfunction to identify high-risk patients should be the standard of care [1]. For sepsis, new criteria (Sepsis-3) have recently been proposed including a qSOFA score as a rapid screening tool [2]. The qSOFA was validated within various datasets of heterogeneous sepsis patients [3] and consists of the same three clinical parameters used in CRB but with different cut-offs for tachypnea (respiratory rate ≥22/min vs. ≥30/min in CRB) and hypotension (systolic blood pressure ≤100 mmHg vs. <90 mmHgsys or ≤60 mmHgdias) [2, 4]. A cut-off of ≥2 qSOFA-criteria provided mortality prediction as good as the more complex SOFA score in non-ICU patients. However, the original datasets used to establish qSOFA were not stratified according to...


Organ Dysfunction Sofa Score Mortality Prediction Multicenter Validation Acute Organ Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Grants: CAPNETZ was founded by a BMBF Grant (01KI07145) 2001-2011. CAPNETZ is a multidisciplinary approach to better understand and treat patients with community-acquired pneumonia. The network has only been made possible by the contribution of many investigators. We are especially indebted to the work of the investigators in the local clinical centers (LCC) who established and kept contact to all practitioners, physicians, and respiratory specialists cooperating within the network. Members of the CAPNETZ study group except the authors: M. Dreher, C. Cornelissen (Aachen); W. Knüppel (Bad Arolsen); D. Stolz (Basel); N. Suttorp, P. Creutz (Berlin, Charité); T. Bauer, T. Sabha (Berlin); W. Pankow, A. Lies, D. Thiemig (Berlin-Neukölln); B. Hauptmeier, S. Ewig, D. Wehde (Bochum); M. Prediger, S. Schmager (Cottbus); G. Höffken, M. Kolditz, B. Schulte-Hubbert, S. Langner (Dresden), T. Welte, G. Barten, M. Abrahamczik, J. Naim, W. Kröner, T. Illig, N. Klopp (Hannover); P. Ravn, A. Vestergaard-Jensen, G. Baunbaek-Knudsen (Hillerød); C. Kroegel, M. Pletz, J. Happe, J. Frosinski, J. Winning, A. Moeser (Jena); K. Dalhoff, K. Dageförde, K. Franzen, F. Hyzy, H. Schmieg, P. Parschke, P. Thiemann, J. Ahrens, T. Hardel (Lübeck); G. Rohde, J. Drijkoningen (Maastricht); H. Buschmann, R. Kröning (Paderborn); H. Schütte (Potsdam), T. Schaberg, I. Hering (Rotenburg/Wümme); C. Kropf-Sanchen (Ulm); T. Illmann, M. Wallner (Ulm); and all study nurses.

Compliance with ethical standards

Conflicts of interest

Dr. Kolditz reports personal fees from Pfizer, Gilead, Novartis, Astra-Zeneca, Basilea, Böhringer-Ingelheim, Bayer, outside the submitted work. Dr. Scherag reports grants from Federal Ministry of Education and Research (BMBF), Germany, during the conduct of the study. Dr. Rohde reports personal fees from Pfizer, Novartis, Bayer, Astra Zeneca and Chiesi outside the submitted work. Dr. Welte reports grants from Ministry of Research and Education, during the conduct of the study; personal fees from AstraZeneca, Bayer, Basilea, Infectopharm, Pfizer, outside the submitted work. Dr. Ewig and Dr. Pletz have nothing to disclose.

Supplementary material

134_2016_4517_MOESM1_ESM.docx (63 kb)
Supplementary material 1 (DOCX 64 kb)


  1. 1.
    Kolditz M, Ewig S, Hoffken G (2013) Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 41:974–984CrossRefPubMedGoogle Scholar
  2. 2.
    Singer M, Deutschman CS, Seymour CW et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801–810CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:762–774CrossRefPubMedGoogle Scholar
  4. 4.
    Lim WS, van der Eerden MM, Laing R et al (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wang JY, Chen YX, Guo SB, Mei X, Yang P (2016) Predictive performance of quick Sepsis-related Organ Failure Assessment for mortality and intensive care unit admission in patients with infection at the ED. Am J Emerg Med. doi: 10.1016/j.ajem.2016.06.015 Google Scholar
  6. 6.
    Chen YX, Wang JY, Guo SB (2016) Use of CRB-65 and quick Sepsis-related Organ Failure Assessment to predict site of care and mortality in pneumonia patients in the emergency department: a retrospective study. Crit Care 20:167CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2016

Authors and Affiliations

  • Martin Kolditz
    • 1
  • André Scherag
    • 2
  • Gernot Rohde
    • 3
    • 7
    • 8
  • Santiago Ewig
    • 4
  • Tobias Welte
    • 5
    • 7
    • 8
  • Mathias Pletz
    • 6
    • 7
  • on behalf of the CAPNETZ Study Group
  1. 1.Division of Pulmonology, Medical Department I, University Hospital Carl Gustav CarusTechnische Universität DresdenDresdenGermany
  2. 2.Research Group Clinical Epidemiology, Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC)Jena University HospitalJenaGermany
  3. 3.Department of Respiratory MedicineMaastricht University Medical CenterMaastrichtThe Netherlands
  4. 4.Thoraxzentrum Ruhrgebiet, Department of Respiratory and Infectious DiseasesEVK Herne and Augusta-Kranken-Anstalt BochumBochumGermany
  5. 5.Department of Respiratory MedicineMedizinische Hochschule HannoverHannoverGermany
  6. 6.Center for Infectious Diseases and Infection ControlJena University HospitalJenaGermany
  7. 7.CAPNETZ STIFTUNGHannoverGermany
  8. 8.Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL)HannoverGermany

Personalised recommendations